Skip to main content

Piroptosis e infiltración de células T en tumor local, por nanotoxinas dirigidas, y su combinación con inhibidores de control inmune y agonistas de revigorización (EfectPiroTIL)

PI24/01476

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2024
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU
Execution centre INSTITUT DE RECERCA SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein

  • Álamo, Patricia|||0000-0003-0510-5701
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
Endocrine-like dynamic protein depots can be fabricated in vitro through the coordination of divalent zinc ions (Zn) with solvent-exposed histidine residues on functional proteins, leading to their controlled aggregation. The resulting microparticles, under physiological conditions, undergo progressive disintegration due to spontaneous Zn dilution, enabling a time-sustained release of the protein components. These chemically pure protein-based materials represent promising drug delivery platforms, with demonstrated efficacy in oncology, vaccinology, tissue regeneration, and antibacterial therapies. To enable systemic delivery of the embedded protein, alternative administration routes are potentially suited, but their effectiveness in terms of biodistribution and accumulation in target tissues remains unexplored. Using a CXCR4 cancer mouse model, we investigated the tumor targeting and permanence of a self-assembling, CXCR4-binding fluorescent protein administered in the form of secretory granules via subcutaneous, intramuscular, or intraperitoneal injection. Our data reveal that subcutaneous administration supports prolonged protein retention at the injection site, its release within the local draining lymphatic vessels, extended circulation time, and significantly higher tumor accumulation 10 days post-injection. Compared to intramuscular and intraperitoneal routes, the subcutaneous pathway presents clear advantages, potentially allowing reduced dosing frequency in protein-based therapies aimed at maintaining steady systemic and target tissue levels.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates

  • Rueda, Ariana|||0000-0001-7588-9279
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Aviñó, Ana|||0000-0003-3047-738X
  • Fabrega, Carme|||0000-0003-3816-7634
  • Eritja, Ramon|||0000-0001-5383-9334
  • Paez, David|||0000-0002-5596-6588
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an alternative, we previously developed a multivalent protein nanocarrier (T22-GFP-H6) displaying the CXCR4-targeting peptide T22, which offers super-selective tumor accumulation driven by CXCR4 overexpression. This innovative nanovehicle showed favorable biodistribution for targeted delivery of antitumor drugs, including monomethyl auristatin E (MMAE), in a first-generation stochastic nanoconjugate format. However, unlike ADCs, where conjugation strategy is known to influence pharmacokinetics and efficacy, these parameters remain largely unexplored in non-antibody multivalent nanocarriers. Here, we evaluated the impact of precise payload accommodation using two site-specific strategies that attach a single MMAE molecule at distinct structural sites, and we compared them with first-generation nanoconjugates. The conjugation strategy substantially affected the biodistribution and antitumor efficacy, with a solvent-exposed cysteine-conjugation distal to the targeting ligand proving most effective. At equimolar nanocarrier dosing, this construct achieved tumor control similar to the stochastic conjugate in a disseminated hematologic malignancy despite an approximately 4-fold lower MMAE load (drug-to-protein ratio, DPR = 1 vs DPR ≈ 4). Moreover, at equimolar MMAE dosing, it clearly outperformed both the stochastic conjugate and the alternative site-directed design. These findings align with trends in advanced ADCs and provide practical design rules for rational, site-specific conjugation in next-generation protein-based nanomedicines aimed at enabling dose-sparing in oncology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Arena, Lourdes Ailen|||0009-0006-1863-3895
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The biological activity of therapeutic proteins, upon intracellular delivery, is dramatically minimized by lysosomal proteolytic digestion. This is a limitation when developing cell-targeted pharmaceuticals that penetrate target cells via receptor recognition and endosomal engulfment. Since proteins benefit from functional and conformational versatility, editable by genetic engineering, endosomolytic protein domains are often fused to the functional polypeptide to promote their cytosolic delivery, aiming at minimizing proteolysis in mature lysosomes. This straightforward strategy has, however, rendered irregular results, linked to the fusogenic nature of most of the tested domains. Alternatively, proteolysis of protein drugs might be controlled by bypassing the lysosomal route, forcing an unconventional traffic of the uptaken protein material to be secreted from the endoplasmic reticulum (ER). This possibility, used in nature by several plant and microbial proteins, has been evaluated here by functionalizing a protein-only antitumoral drug, based on a cell-targeted diphtheria toxin, with a C-terminal KDEL motif. Thus, if KDEL were able to reprogram the intracellular trafficking, KDEL-tagged cell delivered proteins would be expected to avoid the lysosomal degradation, resulting in enhanced stability and activity. The obtained results validate this hypothesis and point out KDEL as a promising functional agent in cell-targeted protein drugs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Biomimetic Protein Materials for Adjuvant-Free Dermal Penetration

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Escribano-Ferrer, Elvira|||0000-0001-7837-9506
  • Huaca, Vanesa
  • Miranda-Tovar, Eva
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
The effective dermal delivery of functional proteins could substantially improve therapeutic options for common skin disorders, in which current lipid-based or invasive strategies face efficacy and safety limitations. We report a biomimetic protein depot platform based on granular, nontoxic amyloids generated through Zn-mediated coordination of hexahistidine-tagged proteins. Functionalization of these materials with either the cell-penetrating peptide R9 or the tight junction modulator c-CPE, the C-terminal region of the Clostridium perfringens enterotoxin, enabled a systematic evaluation of transdermal penetration in mouse models. Whereas plain and R9-functionalized granules showed restricted permeation, c-CPE-functionalized granules achieved consistent distribution through the dermis into the hypodermal layers. These findings establish self-assembled protein amyloids as a promising and adaptable class of biomaterials for dermal protein delivery. Also, the ability of c-CPE to enhance permeability without auxiliary adjuvants, lipids, or invasive methods highlights the translational potential of this system for clinically applicable, noninvasive management of cutaneous conditions.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model

  • Garcia León, Annabel|||0000-0003-3007-9306
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Rueda, Ariana|||0000-0001-7588-9279
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sierra, Jorge|||0000-0002-7966-0356
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Acute myeloid leukemia (AML) presents major clinical challenges due to chemoresistance and high relapse rates, primarily driven by therapy-resistant leukemic stem cells (LSCs) within the bone marrow. To address this issue, we developed T22-HSNBT-H6-MMAE, a novel humanized nanoconjugate designed to target CXCR4 cells while delivering the cytotoxic payload monomethyl auristatin E (MMAE). CXCR4 signaling pathway plays a critical role in LSC survival by preserving stem-like properties and activating protective mechanisms that promote treatment resistance. Moreover, CXCR4 is overexpressed in approximately 50 % of AML patients and is associated with poor prognosis and high relapse rates. We evaluated the therapeutic potential of T22-HSNBT-H6-MMAE using in vitro assays with AML cell lines and primary patient samples, as well as in vivo studies in a disseminated AML mouse model. Our results demonstrated that T22-HSNBT-H6-MMAE exerts a CXCR4-dependent cytotoxic effect through mitotic catastrophe and apoptosis induction in CXCR4 AML cell lines. In vivo evaluation in a disseminated CXCR4 AML mouse model showed potent antineoplastic activity, with complete suppression of leukemic dissemination and significantly prolonged survival, all without systemic toxicity. Notably, the nanoconjugate remained effective even in models with extensive bone marrow involvement and exhibited activity against diverse patient-derived CXCR4 AML blasts, while sparing healthy donor bone marrow and peripheral blood mononuclear cells (PBMCs) from significant toxicity. Collectively, these findings highlight T22-HSNBT-H6-MMAE as a promising therapeutic candidate for a broad range of AML patients, offering selective antineoplastic activity against CXCR4 leukemic cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.